The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

AFL great, turned Cerutty Macro Fund portfolio manager, Chris Judd is with HP Rx founder and managing partner Hashan De Silva for today’s Talk Ya Book.

They discuss CurveBeam AI (ASX:CVB), a company in which Mr De Silva is a director. Mr De Silva holds 565,493 ordinary shares, millions of options and 320,928 indirect shares.

The company’s developed a CT scanning device, called HiRise, that works when a patient is weight-bearing, providing imaging while patients are standing. The images can be done within an orthopaedic centre, and release lower radiation levels.

CurveBeam has a market cap of $36 million and was trading at 16 cents (May 28).

KP Rx invests in a diverse range of biotech, medical device, diagnostic, and health tech companies located predominantly in Australia and New Zealand. It is backed by Karst Peak Capital.

Talk Ya Book was created by Chris Judd in 2019 as a show where fund managers could share their highest conviction investment idea but more importantly showcase their investment framework to the public.

Disclaimer: Juddcorp Pty Ltd ACN 635 629 631 is a corporate authorised representative (CAR) (CAR Number 1300536) of Boutique Capital Pty Ltd ACN 621 697 621 AFSL 508011.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
Pancreatic cancer 3D illustration

Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win

Radiopharm Theranostics (ASX:RAD) has seen the safety profile of its pancreatic cancer imaging drug RAD 301…
The Market Online Video

Bigtincan’s Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider…
Medical professional holding a tablet

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy…